Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:29 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)
NCT04439071 · PTC Therapeutics · PHASE2/PHASE3 · terminated · last registry update 2023-06-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision” | – | Registry record, PTC Therapeutics |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against DHODH within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-04-17Phase 3 first posted: Sanofi, Tolebrutinib + Placebo (NCT06372145)
- 2024-03-05Results posted on the registry: Immunic AG, IMU-838 + Placebo (NCT03341962)
- 2024-03-05Also stopped (terminated): Immunic AG, IMU-838 + Placebo (NCT03341962)
- 2023-11-21Phase 3 first posted: Sanofi, Frexalimab + Teriflunomide (NCT06141473)
- 2023-11-07Also stopped (terminated): Clear Creek Bio, Inc., Brequinar Sodium + Dipyridamole 75 MG (NCT05166876)
- 2023-02-06Results posted on the registry: Clear Creek Bio, Inc., Brequinar Sodium + Dipyridamole 75 MG (NCT05166876)
- 2022-10-20Results posted on the registry: Providence Health & Services, teriflunomide (NCT01970410)
- 2022-08-08Results posted on the registry: Clear Creek Bio, Inc., Brequinar/Brequinar + Ribavirin (NCT03760666)
- 2022-08-08Also stopped (terminated): Clear Creek Bio, Inc., Brequinar/Brequinar + Ribavirin (NCT03760666)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision